cellectis (CLLS)

Cellectis (CLLS), a clinical-stage biotechnology company developing gene-edited cell and gene therapies, reported financial results for the second quarter of 2026.

CELLECTIS (CLLS) reported Loss for second quarter of -$21.82 million The company's earnings came in at -$21.82 million, or -$0.22 per share. This compares with -$23.74 million, or -$0.24 per share, last year. Excluding items, CELLECTIS reported adjusted earnings of -$19.53 million or -$0.19 per...

Cellectis S.A. (CLLS), a clinical-stage biotechnology company, announced that the U.S. Food and Drug Administration, or FDA, has granted the Regenerative Medicine Advanced Therapy (RMAT) designation to its CAR-T cell therapy candidate Lasmecabtagene timgedleucel, also known as "lasme-cel," for the treatment...

Cellectis S.A. (CLLS) shares climbed 7.35 percent to $4.41, gaining $0.30 on Thursday, after the biotechnology company announced it is hosting an R&D Day in New York City.

Cellectis S.A.(CLLS), a biotechnology company focused on gene-editing technologies, presented promising data at the American Association for Cancer Research - Immuno-oncology or AACR-IO 2025. The company showcased a novel strategy aimed at enhancing CAR T cell efficacy in treating solid tumors. The...